Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 23, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 717,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,682.50 pence per share; lowest price paid was 1,664.00 pence per share.
- Treasury Holdings (Settled): 511,868,412 shares (9.46% of total issued share capital).
- Treasury Holdings (Including Unsettled): 514,119,412 shares (10.49% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,901,415,084 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 717,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.49% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (511,868,412 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.49% held in Treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (4,901,415,084 shares in issue excluding Treasury).
- Review the price paid per share (1,664.00 to 1,682.50 pence) against market prices on August 23, 2013.